source
- Cancer and immune-focused biotech firms capture over $3.9 billion of H1 2026 venture capitalBioPharma Dive data show that cancer and immune disease biotech companies accounted for more than 40% of the biotech firms receiving venture funding in the first half of 2026. Of the roughly $9 bi…
- Novartis to spend $1.1 billion upfront acquiring Myricx Bio and its next-gen ADC platformNovartis announced Monday it will invest $1.1 billion in an upfront payment to acquire Myricx Bio. Myricx Bio brings an antibody-drug conjugate (ADC) payload platform that the Swiss group believes…